Assessment of the use of spironolactone on the endothelial glycocalyx in high blood pressure

Assessment of spironolactone on the endothelial glycocalyx in hypertension

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12616000933459

Acronym

ASGARD

Enrollment

Registered

2016-07-13

Start date

2016-07-15

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The glycocalyx is a particle that is important in maintaining blood vessel health. High blood pressure is common, closely related to salt regulation, and affects the health of blood vessels. Animal studies have shown that the glycocalyx is affected in high blood pressure. Laboratory studies indicate that the use of spironolactone, a common blood pressure medication, can offset the effects of a high-salt environment on the glycocalyx. The purpose of this study is to assess if the glycocalyx is affected in people who have high blood pressure, whether the glycocalyx can be improved with good blood pressure control, and whether spironolactone has any additional protective benefits on the glycocalyx.

Interventions

Spironolactone 25mg, oral tablet, once daily. Adherence to be monitored by questionnaire and return of empty drug packets.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Hypertension on 24-hr ambulatory blood pressure monitoring (>140/90mmHg) and/or hypertensive event e.g. stroke Microalbuminuria (spot urine ACR > 3 mg/mmol)

Exclusion criteria

Malignancy, pregnancy, inability to consent, known haematological disorders, eGFR <60

Outcome results